Ocular Therapeutix (NSDQ:OCUL) said today that its post-surgical ocular pain reliever, Dextenza, met both primary endpoints in a pivotal trial for the treatment of post-surgical ocular inflammation and pain. The product is a bioresorbable intracanalicular insert, designed for drug release to the ocular surface for up to 30 days.
The randomized, double-masked study enrolled 438 patients who were undergoing clear corneal cataract surgery at 21 sites throughout the U.S to compare the Dextenza insert with a sham control procedure.
Get the full story at our sister site, Drug Delivery Business News.